## 10-Year Financial / Non-Financial Data

(For the fiscal years as of / ended March 31)

|  | 2008/3 | 2009/3 | 2010/3 |
| :---: | :---: | :---: | :---: |
| Net sales | 1,128,875 | 980,803 | 883,086 |
| Selling, general and administrative (SG\&A) expenses | 396,678 | 418,558 | 347,125 |
| Percentage of net sales (\%) | 35.1\% | 42.7\% | 39.3\% |
| Percentage of net sales excluding R\&D expenditures (\%) | 29.3\% | 35.5\% | 32.3\% |
| Operating income | 112,826 | 42,722 | 61,160 |
| Percentage of net sales (\%) | 10.0\% | 4.4\% | 6.9\% |
| Ordinary income ${ }^{* 1}$ | 97,312 | 25,679 | 46,075 |
| Net income (loss) | 54,625 | $(50,561)$ | 52,527 |
| Percentage of net sales (\%) | 4.8\% | - | 5.9\% |
| EBITDA margin*2 (\%) | 14.0\% | 12.8\% | 13.3\% |
| EBITDA margin (Medical Business)*3 (\%) | 31.1\% | 27.0\% | 29.2\% |
| R\&D expenditures | 65,928 | 70,010 | 61,850 |
| Percentage of net sales (\%) | 5.8\% | 7.1\% | 7.0\% |
| Capital expenditures*4 | 50,070 | 55,632 | 34,323 |
| Depreciation and amortization | 37,497 | 44,594 | 43,099 |
| Amortization of goodwill | 7,899 | 37,881 | 12,918 |
| Average exchange rate |  |  |  |
| Yen / U.S. dollar | 114.28 | 100.54 | 92.85 |
| Yen / Euro | 161.53 | 143.48 | 131.15 |

Financial indicators

| Total assets*5 | 1,217,172 | 1,038,253 | 1,104,528 |
| :---: | :---: | :---: | :---: |
| Total net assets ${ }^{* 5}$ | 244,281 | 110,907 | 163,131 |
| Equity ratio (\%) | 19.1\% | 10.0\% | 14.1\% |
| Interest-bearing debt | 656,756 | 642,839 | 661,481 |
| Net debt | 533,475 | 505,763 | 454,698 |
| Inventories | 110,379 | 95,540 | 89,959 |
| Inventory turnover period (months) | 1.2 | 1.2 | 1.3 |
| Cash and cash equivalents at end of year | 119,842 | 132,720 | 203,013 |
| Cash flows from operating activities | 88,204 | 36,864 | 76,245 |
| Cash flows from investing activities | $(274,104)$ | $(15,964)$ | $(20,967)$ |
| Cash flows from financing activities | 134,401 | $(3,751)$ | 17,355 |
| Return on equity (ROE) (\%) | 24.4\% | (30.2\%) | 40.6\% |
| Return on assets (ROA) (\%) | 9.3\% | 4.1\% | 4.9\% |
| Net income (loss) per share (yen) | 202.11 | (188.85) | 194.90 |
| Total equity per share (yen) | 861.58 | 387.31 | 576.63 |
| Price earnings ratio (PER)*6 (times) | 14.9 | - | 15.4 |
| Price book-value ratio (PBR) (times) | 3.5 | 4.1 | 5.2 |
| Outstanding market value (billions of yen) | 8,193 | 4,286 | 8,138 |
| Cash dividends per share (yen) | 40 | 20 | 30 |

## Non-financial indicators

Number of employees ${ }^{\star 7}$

| 35,772 | 36,503 | 35,376 |
| ---: | ---: | ---: |
| $(-)$ | $(-)$ | $(-)$ |
| $65.4 \%$ | $62.1 \%$ | $63.3 \%$ |
| $0.9 \%$ | $0.8 \%$ | $0.9 \%$ |
| $1.6 \%$ | $1.7 \%$ | $1.8 \%$ |

*1. Ordinary income is calculated using the following formula: Ordinary income $=$ Operating income + Interest income - Interest expense $\pm$ Equity in gain (loss) of affiliates $\pm$ Other gains (losses) except for extraordinary gains (losses) defined in Japanese GAAP
Ordinary income is not presented in the consolidated statements of operations since the consolidated financial statements have been reformatted for the convenience of readers outside Japan as described in the notes to the financial statements.
*2. At the Company, EBITDA is calculated using the following assumptions: EBITDA = Operating income + Depreciation and amortization that is included in cost of sales or SG\&A expenses + Amortization of goodwill that is included in SG\&A expenses. EBITDA margin = EBITDA $/$ Net sales
*3. At the Company, EBITDA (Medical Business) is calculated using the following assumptions: EBITDA = Segment profit in the Medical Business + Depreciation and amortization that is included in cost of sales or SG\&A expenses + Amortization of goodwill that is included in SG\&A expenses. EBITDA margin (Medical Business) = EBITDA (Medical Business) / Net sales

|  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $2011 / 3$ |  |  |  |  |  |  |

*4. Capital expenditures are calculated based on the definition of capital expenditure in accordance with ASBJ Statement No. 17 "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information."
*5. In line with the issuance of IAS No. 19 "Employee Benefits" (revised on June 16, 2011) to be applied for fiscal years beginning on or after January 1, 2013, certain overseas subsidiaries adopted IAS No. 19 effective from the fiscal year ended March 31, 2014, and changed their method of recognizing actuarial gain or loss. This change has been applied retroactively to the figures for the fiscal year ended March 31, 2013.
*6. Price earnings ratio (PER) for the fiscal years ended March 31, 2012 and 2015 are omitted as Olympus recorded net loss for these fiscal years.
7. The average number of temporary employees is stated in parentheses from the fiscal year ended March 31, 2011, as the number of temporary employees is over $10 \%$ of the total number of employees.
${ }^{*}$. Figures for percentage of women in managerial roles only include individuals in Japan.
*9. Figures for percentage of employees with disabilities are as of June 1 of the respective year and only include individuals in Japan

